Loading
APTN-101 is a two-armed antibody from Adaptin Bio that steers a patient's own T cells against brain tumour cells carrying a faulty growth receptor. It is in a first trial in people with glioblastoma at Duke University.
APTN-101 is Adaptin Bio's EGFRvIII x CD3 bispecific (BRiTE). The FDA accepted an investigator-initiated IND for a single-dose trial in May 2023 and a multi-dose amendment in October 2025; institutional review board approval for the multi-dose trial in glioblastoma came in March 2026, and Duke University opened the investigator-initiated phase 1 trial, "A Phase I Study of hEGFRvIII-CD3 bi-scFv (BRiTE) in Patients with WHO Grade IV Malignant Glioma", in August 2026.
A fully human bispecific single-chain antibody that binds EGFRvIII, a mutant form of EGFR found on tumour cells, and CD3 on T cells, redirecting the patient's T cells to kill the tumour; Adaptin Bio's BRiTE approach uses activated T cells to carry it into the brain. Connects to CD3.
1.One arm of APTN-101 binds CD3 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"APTN-101" OR ABSTRACT:"APTN-101" OR TITLE:"hEGFRvIII-CD3 bi-scFv" OR ABSTRACT:"hEGFRvIII-CD3 bi-scFv" OR TITLE:"EGFRvIII BRiTE" OR ABSTRACT:"EGFRvIII BRiTE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about APTN-101, not a curated reading list.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3, T-cell engagers (bispecific) and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Shares CD3 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/